Skip to main content
. Author manuscript; available in PMC: 2015 Sep 1.
Published in final edited form as: Int J Biol Markers. 2011 Sep 21;26(3):141–152. doi: 10.5301/JBM.2011.8613

Fig. 2.

Fig. 2

Performance of multimarker panels for the discrimination of ovarian cancer patients from controls. The top performing urine biomarker panels for the discrimination of ovarian cancer patients from healthy (A) and benign (B) controls were identified using the Metropolis-Monte Carlo (MMC) algorithm. Panel performance was compared to serum CA 125 measured in the same group. The impact of adding serum CA 125 to the top urine biomarker panel was evaluated for each comparison. s, serum; u, urine.